Skip to main content

Table 1 Baseline characteristics

From: Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI) - a pilot randomized controlled trial of hemofiltration versus hemodialysis: a Canadian Critical Care Trials Group project

 

CVVH (n= 39)

CVVHD (n= 38)

Age, years

58.8 ± 13.7

64.3 ± 14.3

Female

14 (36%)

16 (42%)

Weight, kg

86.6 ± 31.5

89.2 ± 26.4

Days from ICU admission to randomization

2 (1, 4)

2 (1, 3)

SOFA score

16.3 ± 3.3

15.5 ± 3.0

Premorbid conditions

Hypertension

19 (49%)

26 (68%)

Diabetes mellitus

9 (23%)

9 (24%)

Chronic kidney disease

5 (13%)

13 (34%)

Acute kidney injury risk factors

Sepsis

31 (79%)

32 (84%)

Cardiopulmonary bypass in past 7 days

1 (3%)

4 (11%)

IV contrast in past 7 days

9 (23%)

6 (16%)

Physiologic parameters

Urine output, mL/24 hr

125 (60, 245)

135 (46, 251)

Minimum systolic BP during 24 hr before enrolment, mmHg

94.2 ± 16.5

86.1 ± 13.5

Minimum diastolic BP during 24 hr before enrolment, mmHg

48.9 ± 8.6

47.2 ± 9.4

Laboratory parameters

Serum creatinine, µmol/L

276 (194, 352)

246 (155, 325)

Urea, mmol/L

25.8 ± 38.1

17.6 ± 12.7

Potassium, mmol/L

4.3 ± 0.7

4.1 ± 0.6

Bicarbonate, mmol/L

20.5 ± 5.9

20.2 ± 5.3

Hemoglobin, g/L

86.1 ± 16.3

90.0 ± 15.2

Platelets, × 109/L

109.6 ± 82.6

127.2 ± 80.9

WBC, × 109/L

20.2 ± 43.3

16.9 ± 10.6

ICU interventions

Duration of RRT prior to randomization, hours

8 (0, 19)

13 (1.0, 20.5)

Mechanical ventilation

37 (95%)

36 (95%)

Vasopressors

34 (87%)

35 (92%)

Total parenteral nutrition

1 (3%)

2 (5%)

  1. Continuous data are displayed as mean ± SD or medians (interquartile range), as appropriate. Categorical variables are displayed as n (%). CRRT, continuous renal replacement therapy; CVVH, continuous venovenous hemofiltration; CVVHD, continuous venovenous hemodialysis; BP, blood pressure; RRT, renal replacement therapy; SOFA, Sequential Organ Failure Assessment; WBC, White blood cell.